BRIVANIB (C005B-308607)

Biochem/physiol Actions

Brivanib (BMS-540215) is an orally active, ATP-competitive FGF & VEGF receptor tyrosine kinase inhibitor (VEGFR-1/2/3 IC50 = 380/25/10 nM; FGFR-1/2/3 IC50 = 148/125/68 nM). Brivanib inhibits VEGF-stimulated and basic FGF-stimulated proliferation in endothelial cultures (IC50 = 40 & 276 nM, respectively) and displays antitumor efficacy in vivo (30-90 mg/kg via daily p.o. in mice with H3396 xenografts).

UPC:

51323001

Condition:

New

Weight:

1.00 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

MPN:

SML3671-5MG

CAS:

649735-46-6